Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.
diet preference
dual GIP/GLP-1 receptor agonists
food intake
obesity
tirzepatide
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
04
08
2022
received:
03
07
2022
accepted:
13
08
2022
pmc-release:
01
01
2024
pubmed:
3
9
2022
medline:
15
12
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
To investigate the role of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists alone or combined with glucagon-like peptide-1 receptor (GLP-1R) agonists to regulate palatable food intake and the role of specific macronutrients in these preferences. To understand this regulation, we treated mice and rats on several choice diet paradigms of chow and a palatable food option with individual or dual GIPR and GLP-1R agonists. In mice, the dual agonist tirzepatide suppressed total caloric intake, while promoting the intake of chow over a high fat/sucrose diet. Surprisingly, GIPR agonism alone did not alter food choice. The food intake shift observed with tirzepatide in wild-type mice was completely absent in GLP-1R knockout mice, suggesting that GIPR signalling does not regulate food preference. Tirzepatide also selectively suppressed the intake of palatable food but not chow in a rat two-diet choice model. This suppression was specific to lipids, as GLP-1R agonist and dual agonist treatment in rats on a choice paradigm assessing individual palatable macronutrients robustly inhibited the intake of Crisco (lipid) without decreasing the intake of a sucrose (carbohydrate) solution. Decreasing preference for high-caloric, high-fat foods is a powerful action of GLP-1R and dual GIPR/GLP-1R agonist therapeutics, which may contribute to the weight loss success of these drugs.
Identifiants
pubmed: 36054312
doi: 10.1111/dom.14843
pmc: PMC10362946
mid: NIHMS1900498
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
56-67Subventions
Organisme : NIDDK NIH HHS
ID : F32 DK127591
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK021397
Pays : United States
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Diabetes Obes Metab. 2021 Oct;23(10):2344-2353
pubmed: 34189834
Peptides. 2013 Sep;47:115-23
pubmed: 23891652
PLoS One. 2012;7(7):e40156
pubmed: 22802954
Mol Metab. 2019 Feb;20:51-62
pubmed: 30578168
Cell Metab. 2021 Apr 6;33(4):833-844.e5
pubmed: 33571454
Sci Transl Med. 2013 Oct 30;5(209):209ra151
pubmed: 24174327
Sci Rep. 2019 Oct 30;9(1):15582
pubmed: 31666597
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Diabetes. 2017 Feb;66(2):372-384
pubmed: 27908915
Endocrinology. 2012 Feb;153(2):647-58
pubmed: 22128031
Diabetes. 2021 Nov;70(11):2545-2553
pubmed: 34380697
Am J Physiol Regul Integr Comp Physiol. 2016 May 15;310(10):R885-95
pubmed: 27030669
Am J Physiol Endocrinol Metab. 2013 Dec 1;305(11):E1367-74
pubmed: 24105414
J Lipid Res. 2012 Nov;53(11):2256-65
pubmed: 22904345
N Engl J Med. 2021 Aug 5;385(6):503-515
pubmed: 34170647
Neuropsychopharmacology. 2018 Sep;43(10):2000-2008
pubmed: 29497166
Acta Pharmacol Sin. 2012 Feb;33(2):194-200
pubmed: 22301859
Mol Metab. 2018 Dec;18:3-14
pubmed: 30473097
Cell Metab. 2019 Nov 5;30(5):987-996.e6
pubmed: 31447324
Am J Physiol Regul Integr Comp Physiol. 2011 Jun;300(6):R1266-77
pubmed: 21411768
Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394
pubmed: 33030356
Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2489-2494
pubmed: 31405666
Diabetes Obes Metab. 2018 Jan;20(1):60-68
pubmed: 28598027
Int J Mol Sci. 2021 Jan 18;22(2):
pubmed: 33477478
Physiol Behav. 2017 Aug 1;177:4-12
pubmed: 28366815
Biochem Biophys Res Commun. 2017 Aug 19;490(2):247-252
pubmed: 28610922
Lancet. 2021 Jul 10;398(10295):143-155
pubmed: 34186022
Am J Physiol Regul Integr Comp Physiol. 2013 Jul 1;305(1):R68-77
pubmed: 23616105
J Clin Endocrinol Metab. 2022 Jan 18;107(2):363-378
pubmed: 34608929
Physiol Behav. 2009 Jul 14;97(5):609-15
pubmed: 19303887
Endocrinology. 2011 Aug;152(8):3103-12
pubmed: 21693680
Mol Metab. 2021 Apr;46:101090
pubmed: 32987188
J Neurosci. 2012 Apr 4;32(14):4812-20
pubmed: 22492036
JCI Insight. 2020 Mar 26;5(6):
pubmed: 32213703
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
Trends Endocrinol Metab. 2020 Jun;31(6):410-421
pubmed: 32396843
J Neuroendocrinol. 2019 May;31(5):e12718
pubmed: 30958590
Diabetes. 2007 Jan;56(1):8-15
pubmed: 17192459
Diabetes Obes Metab. 2020 Aug;22(8):1417-1424
pubmed: 32250534
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 34003802
Diabetes Obes Metab. 2017 Sep;19(9):1242-1251
pubmed: 28266779
Peptides. 1994;15(2):297-302
pubmed: 8008635